Kuleva S A
Vopr Onkol. 2008;54(6):768-70.
The end results of treatment of Hodgkin's disease are evaluated. Since survival rates for patients receiving risk-adapted programs (DAL-Hd, SPBLKH-05) were higher than in control (MOPP), relevant protocols using lower drug dosage should be recommended in groups of favorable and intermediate risk.